BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, Sellers E. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. J Psychopharmacol 2018;32:1351-61. [PMID: 30269642 DOI: 10.1177/0269881118796814] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ngo Q, Plante DT. An Update on the Misuse and Abuse Potential of Pharmacological Treatments for Central Disorders of Hypersomnolence. Curr Sleep Medicine Rep. [DOI: 10.1007/s40675-022-00227-4] [Reference Citation Analysis]
2 Guerdjikova AI, Romo-Nava F, Blom TJ, Mori N, McElroy SL. Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder. Contemp Clin Trials 2021;110:106587. [PMID: 34610482 DOI: 10.1016/j.cct.2021.106587] [Reference Citation Analysis]
3 Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol. Pharmacol Res Perspect 2021;9:e00855. [PMID: 34423920 DOI: 10.1002/prp2.855] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Heal DJ, Smith SL. Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology. J Psychopharmacol 2021;:2698811211032475. [PMID: 34318734 DOI: 10.1177/02698811211032475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 21.0] [Reference Citation Analysis]
6 Cuomo MC, Sheehan AH, Jordan JK. Solriamfetol for the Management of Excessive Daytime Sleepiness. J Pharm Pract 2021;:8971900211009080. [PMID: 33882756 DOI: 10.1177/08971900211009080] [Reference Citation Analysis]
7 Setnik B, McDonnell M, Mills C, Scart-Grès C, Robert P, Dayno JM, Schwartz JC. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep 2020;43:zsz252. [PMID: 31626696 DOI: 10.1093/sleep/zsz252] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
8 Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clin Pharmacol Drug Dev 2021;10:404-13. [PMID: 32935460 DOI: 10.1002/cpdd.867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Javaheri S, Javaheri S. Update on Persistent Excessive Daytime Sleepiness in OSA. Chest 2020;158:776-86. [PMID: 32147246 DOI: 10.1016/j.chest.2020.02.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
10 Li S, Yang J. Pitolisant for treating patients with narcolepsy. Expert Review of Clinical Pharmacology 2020;13:79-84. [DOI: 10.1080/17512433.2020.1714435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med 2020;68:97-109. [PMID: 32032921 DOI: 10.1016/j.sleep.2019.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
12 Yang J, Gao J. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Review of Clinical Pharmacology 2019;12:723-8. [DOI: 10.1080/17512433.2019.1632705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]